肝硬化合并门静脉血栓形成的相关危险因素分析

摘要/Abstract

摘要： 目的探讨肝硬化合并门静脉血栓形成的相关危险因素。方法回顾性分析2013年6月至2017年6月在新疆医科大学第一附属医院218例肝硬化患者的临床资料,患者中109例为肝硬化并门静脉血栓患者,109例为肝硬化无门静脉血栓的患者。分析两组患者的一般资料、临床表现、并发症、实验室检查及影像学检查资料的结果,组间计量资料比较使用t检验,计数资料比较采用χ²检验,应用非条件Logistic回归模型进行多因素分析、筛选出独立危险因素。结果门静脉血栓的发生与Child-Pugh分级(χ²=20.293,P<0.01)、脾脏切除术(χ²=11.869,P<0.01)、门静脉主干内径宽度(t=3.125,P<0.01)、脾脏的厚度(t=2.283,P=0.024)、血红蛋白(t=-3.751,P<0.01)、白蛋白(t=-3.924,P<0.01)、D-二聚体(t=5.861,P<0.01)、纤维蛋白降解产物(t=3.110,P<0.01)有关,不受性别、年龄、族别、吸烟、病因、白细胞计数、血小板计数、凝血酶原时间、国际标准化比值、部分凝血活酶时间、纤维蛋白原、胱抑素、血肌酐、总胆红素、直接胆红素、丙氨酸转氨酶、碱性磷酸酶、谷胺酰转肽酶、脾静脉内径宽度、脾脏的长径、高血压、糖尿病的影响。两组患者发生腹泻、肝性脑病、肝肾综合征差异无统计学意义(均P＞0.05),腹痛(χ²=4.598)、发热(χ²=7.72)、消化道出血(χ²=18.435)、原发性腹膜炎(χ²=16.987),差异有统计学意义(均P＜0.05)。D-二聚体、门静脉主干内径宽度、Child-Pugh分级、脾脏切除术是肝硬化患者PVT形成的独立危险因素(OR=0.686、0.161、3.193、9.515),均P<0.05)。结论 D-二聚体、门静脉主干内径宽度、Child-Pugh分级、脾脏切除术是肝硬化患者PVT形成的独立危险因素,肝硬化合并PVT可以使患者的临床症状加重,并发症发生率增加。

关键词: 肝硬化, 门静脉血栓形成, 临床特点, 危险因素

Abstract: Objective To investigate clinical characteristics of liver cirrhosis patients with portal vein thrombosis (PVT) and the related risk factors.Methods Clinical data of 218 patients with liver cirrhosis from June 2013 to June 2017 in our hospital were retrospectively analyzed, including 109 cases with PVT and 109 cases without PVT. General information, clinical manifestations, complications, laboratory examinations and imaging data were analyzed. Measurement data were compared by t-test and enumeration data were by chi-square test. Unconditional logistic regression model was applied for analyzing independent risk factors of PVT in liver cirrhosis patients.Results There were no differences in age, gender, nation, smoking, etiology, white blood cell count, platelet count, prothrombin time, international normalized ratio, activated partial prothrombin, fibrinogen, creatinine, cystatin C, total bilirubin, direct bilirubin, alanine aminotransferase, gamma glutamyl transpeptidase, alkaline phosphatase, length of spleen and width of splenic vein between PVT group and non-PVT group. However, Child-Pugh score (χ²=20.293, P=0.0001), splenectomy (χ²=11.869, P=0.001), the width of portal vein (t=3.125, P=0.002), width of spleen (t=2.283, P=0.024), hemoglobin (t=-3.751, P=0.000), albumin (t=-3.924, P=0.000), D-dimer (t=5.861, P=0.000) and fibrin degradation products (t=3.110, P=0.002) were significantly different between PVT group and non-PVT group. Occurrence of diarrhea, hepatic encephalopathy and hepatorenal syndrome showed no significant difference between two groups (P>0.05), but abdominal pain (χ²=4.598, P=0.032), fever (χ²=7.72, P=0.005), upper gastrointestinal bleeding (χ²=18.435, P=0.0001) and spontaneous peritonitis (χ²=16.987, P=0.000) were significantly different between two groups (P<0.05).Conclusion D-dimer, width of portal vein, Child-Pugh score and splenectomy are independent risk factors for PVT in liver cirrhosis patients (OR=0.686, 0.161, 3.193 and 9.515; P=0.0001, 0.007, 0.021 and 0.007, respectively). PVT in liver cirrhosis patients would aggravate clinical symptoms and increase incidence of complications.

Key words: Liver cirrhosis, Portal vein thrombosis, Risk factors, Clinical characteristics

熊静平, 刘海英, 张跃新. 肝硬化合并门静脉血栓形成的相关危险因素分析[J]. 肝脏, 2018, 23(3): 206-209.

XIONG Jing-ping, LIU Hai-ying, ZHANG Yue-xin. Analysis of risk factors for portal vein thrombosis in liver cirrhosis patients[J]. Chinese Hepatolgy, 2018, 23(3): 206-209.

[1]	庄焱, 卢捷, 谢青, 林兰意. 我国丙型肝炎肝硬化患者DAA治疗现状及短期预后的研究[J]. 肝脏, 2020, 25(3): 249-253.
[2]	程静, 徐路, 彭素琼. 肝血流超声参数联合外周血vWF-Ag对肝硬化患者食管静脉曲张出血的预测价值[J]. 肝脏, 2020, 25(3): 260-263.
[3]	沈张平, 王钦君, 季沈杰. 血清miR127-3P与原发性肝癌的相关性研究[J]. 肝脏, 2020, 25(3): 302-305.
[4]	薛宏丽. HBsAg定量在慢性乙型肝炎治疗中的意义[J]. 肝脏, 2020, 25(3): 308-310.
[5]	董叶子, 安莹波. 细菌性肝脓肿的临床特征及其危险因素分析[J]. 肝脏, 2020, 25(3): 325-327.
[6]	陈艳, 林瑞, 陈竹, 王丽. 2012至2018年某院肝硬化并自发性细菌性腹膜炎的病原学及耐药性分析[J]. 肝脏, 2020, 25(2): 166-168.
[7]	郇稳, 史丽璞. 干燥综合征合并原发性胆汁性肝硬化患者的外周血Th17/Treg细胞百分比及临床特征[J]. 肝脏, 2020, 25(2): 155-157.
[8]	孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127.
[9]	薛超, 马文娜, 孙庆文, 李冲杰. 脐带间充质干细胞治疗失代偿期肝硬化12例临床疗效观察[J]. 肝脏, 2020, 25(1): 66-68.
[10]	李松, 张娟. 替诺福韦酯对乙型肝炎肝硬化患者肝纤维化状态与Th1/Th2型细胞因子的影响研究[J]. 肝脏, 2020, 25(1): 54-55.
[11]	田春丽, 梁科峰, 赵玉. 儿童药物性肝损伤的病因及临床特点分析[J]. 肝脏, 2020, 25(1): 31-33.
[12]	孟庆洋, 徐春林, 康鹏. Ox-LDL诱导肝硬化患者巨噬细胞产生ET[J]. 肝脏, 2019, 24(9): 1007-1010.
[13]	刘亚迪, 孙双双, 徐浩, 李成忠. HBV相关慢加急性肝衰竭患者感染特点及危险因素分析[J]. 肝脏, 2019, 24(9): 1015-1019.
[14]	赵开飞, 谭瑞, 蒋国军, 石荣书, 韦鑫佩, 杜松丽. 脾动脉支架限流术治疗肝硬化门静脉高压的实验研究[J]. 肝脏, 2019, 24(9): 1019-1021.
[15]	张学秀, 姚建宁, 张延祯, 李艳乐, 王春峰, 张连峰. ¹³C-美沙西丁呼气试验在原发性胆汁性胆管炎中的临床应用[J]. 肝脏, 2019, 24(9): 1025-1028.

肝硬化合并门静脉血栓形成的相关危险因素分析

Analysis of risk factors for portal vein thrombosis in liver cirrhosis patients

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价